LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?

Photo by freestocks from unsplash

Corresponding author : Byoung Kuk Jang Department of Internal Medicine, Keimyung University School of Medicine, 1035 Dalgubeol-daero, Dalseo-gu, Daegu 42601, Korea Tel: +82-53-258-7720, Fax: +82-53-258-4343 E-mail: [email protected] https://orcid.org/0000-0002-8950-0866 Abbreviations: ADV,… Click to show full abstract

Corresponding author : Byoung Kuk Jang Department of Internal Medicine, Keimyung University School of Medicine, 1035 Dalgubeol-daero, Dalseo-gu, Daegu 42601, Korea Tel: +82-53-258-7720, Fax: +82-53-258-4343 E-mail: [email protected] https://orcid.org/0000-0002-8950-0866 Abbreviations: ADV, adefovir dipivoxil; CHB, chronic hepatitis B; CVR, complete virologic response; ETV, entecavir; FTC, emtricitabine; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; LAM, lamivudine; LdT, telbivudine; NAs, nucleos(t)ide analogues; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate

Keywords: medicine; tenofovir entecavir; response; hepatitis; chronic hepatitis

Journal Title: Clinical and Molecular Hepatology
Year Published: 2020

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.